Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Partitioning defective 6 homolog beta (PARD6B)
- Target
- PARD6B
- Molecular classification
- Other: Adapter/scaffold protein, Polarity complex protein (PAR complex family), Intracellular signaling protein
01
Overview
Partitioning defective 6 homolog beta (PARD6B) is an adaptor/scaffold protein encoded by the PARD6B gene in humans. As a member of the PAR6 family, it regulates cell polarity and asymmetric cell division via a multi-protein complex (the PAR complex), which interacts with PARD3, aPKC, and Rho-family GTPases such as CDC42 and RAC1. PARD6B contains functional domains including a PDZ domain and a semi-CRIB motif, allowing it to link cytoskeletal and polarity signals. Altered expression or function of PARD6B disrupts epithelial polarity, promotes epithelial–mesenchymal transition (EMT), and has been implicated in the progression, invasion, and metastasis of several cancers, including colorectal and ovarian cancer. There are currently no known clinically-approved drugs targeting PARD6B, but it remains of interest for research in oncology and cell biology.
- Other names
- PAR6BPar-6 family cell polarity regulator betaPAR-6 betaPar-6 (partitioning defective 6, C. elegans) homolog betaPar-6 partitioning defective 6 homolog beta (C. elegans)
02
Mechanism of action
Not applicable—no direct drugs are reported to target PARD6B to date. *In principle*, targeting or modulating the **PARD6-PAR3-aPKC complex** could affect downstream signaling in cancer (this is speculative and based on pathway logic, not direct evidence).
03
Biological functions
Cell polarity regulationAsymmetric cell divisionFormation and maintenance of epithelial tight junctionsAdaptor for multi-protein complex formationRegulation of cytoskeletal dynamicsSignal transduction via Rho GTPases
04
Disease associations
Cancer (involved in processes such as epithelial–mesenchymal transition, cell migration, invasion, and tumor growth)Other (possibly in other diseases involving disrupted cell polarity, but primarily studied in cancer contexts)
05
Safety considerations
Targeting cell polarity proteins may risk disruption of normal tissue architecture and homeostasis, potentially affecting epithelial barriers or promoting off-target effects in rapidly dividing tissues (inferred based on the known cellular role of the PAR complex)No additional known therapeutic liabilities or toxicities are reported in the literature as of the current references
06
Biomarkers
No validated clinical biomarkers for patient selection or efficacy monitoring specifically for PARD6BAltered expression of the Par6 family (including PARD6B) has been proposed as a potential research biomarker in cancers where cell polarity and EMT are dysregulated
Beyond the preview
Go deeper on Partitioning defective 6 homolog beta (PARD6B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Partitioning defective 6 homolog beta (PARD6B).